In this study, the administration of AM281, a selective CB1 antagonist, avoid of aspecific effects, or partial agonist activity produced a significant increase in NPY-positive neurons both in ACD group and in controls. The gene discussed is CNR1; the disease is granular corneal dystrophy type II.